A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

In this study researchers are testing Risvutatug rezetecan also known as (Ris-Rez) a new medicine that targets specific proteins (B7-H3) on cancer cells, thereby reducing the cancer's ability to grow and spread. This study specifically aims to evaluate how well Ris-Rez works in treating relapsed SCLC compared to standard treatment topotecan, by checking whether Ris-Rez makes cancers smaller or disappear completely and if it helps participants live longer. The study is also assessing whether Ris-Rez is safe and tolerated well by participants compared to topotecan and provide a better understand

Trial Details

NCT ID
NCT07099898
Phase
PHASE3
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Ris-Rez
  • Topotecan
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Miami, Florida, United States|25.77427,-80.19366
  • Plantation, Florida, United States|26.13421,-80.23184
  • Tamarac, Florida, United States|26.21286,-80.24977
  • East Syracuse, New York, United States|43.06534,-76.07853

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Adults \>18 or the minimum legal adult age at the time the informed consent form is signed
  • Has histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
  • Has received 1 prior platinum-based systemic therapy with a PD- (L)1 inhibitor for at least 2 cycles of therapy and a chemotherapy free-interval of…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →